Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06245746CT.gov UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Umbilical Cord Derived Mesenchymal Stem Cells Exosomes (this asset) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | P1 | CC · 43 |
| Epoetin Alfa | Mayo Clinic | P4 | BBB |
| Erythropoietin | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| Epoetin Beta | Institut du Cancer de Montpellier - Val d'Aurelle | P4 | BBB |
| Ferric Carboxymaltose [Ferinject] | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | P4 | BBB |
| Darbepoetin Alfa | Amgen | P3 | BBB |
| Cyclophosphamide | OHSU Knight Cancer Institute | P4 | BBB |
| Luspatercept | Guangdong Second Provincial General Hospital | P4 | BBB |
| Ferric Cation | National Cancer Center, Korea | P4 | BBB |
+42 more in the Anemia cohort
Other indications for Umbilical Cord Derived Mesenchymal Stem Cells Exosomes
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Frontotemporal Dementia | — | P1/2 | CCC · 48 |
| Alzheimer Disease | — | P1/2 | CCC · 48 |
| Thrombocytopenia | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Umbilical Cord Derived Mesenchymal Stem Cells Exosomes in Anemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/umbilical-cord-derived-mesenchymal-stem-cells-exosomes-anemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →